Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -3.63% is 331% below its 5-year average of 1.57%, around the middle of its 5-year range (-259.38%–277.30%).
118.45% below its 12-month average of 19.68%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -29.33%.
OPERATING MARGIN
-3.63%
OPERATING MARGIN AVG TTM
19.68%
OPERATING MARGIN AVG 3Y
-40.31%
OPERATING MARGIN AVG 5Y
1.57%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-118.45%
CURRENT VS 3Y AVG
+90.99%
CURRENT VS 5Y AVG
-331.49%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 845 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Maravai LifeSciences Holdings, Inc.
Market Cap
$2.29B
Operating Margin
-3.63%
TTM Avg
19.68%
3Y Avg
-40.31%
5Y Avg
1.57%
Market Cap
$2.28B
Operating Margin
24.03%
TTM Avg
25.35%
3Y Avg
27.79%
5Y Avg
25.07%
Market Cap
$2.33B
Operating Margin
-340.16%
TTM Avg
-365.34%
3Y Avg
-352.03%
5Y Avg
-361.50%
Market Cap
$2.33B
Operating Margin
15.25%
TTM Avg
15.68%
3Y Avg
15.36%
5Y Avg
13.51%
Market Cap
$2.34B
Operating Margin
-32.45%
TTM Avg
-449.54%
3Y Avg
-390.50%
5Y Avg
-1635.66%
Market Cap
$2.36B
Operating Margin
42.26%
TTM Avg
35.06%
3Y Avg
13.24%
5Y Avg
-28.82%
Market Cap
$2.38B
Operating Margin
-42.22%
TTM Avg
-21.11%
3Y Avg
-21.11%
5Y Avg
-21.11%
Market Cap
$2.38B
Operating Margin
-867.87%
TTM Avg
-840.98%
3Y Avg
-774.76%
5Y Avg
-1234.34%
Market Cap
$2.40B
Operating Margin
-0.74%
TTM Avg
-3.89%
3Y Avg
-12.55%
5Y Avg
-17.88%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maravai LifeSciences Holdings, Inc. (MRVI) | $2.29B | -3.63% | 19.68% | -40.31% | 1.57% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 24.03% | 25.35% | 27.79% | 25.07% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.33B | -340.16% | -365.34% | -352.03% | -361.50% |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 15.25% | 15.68% | 15.36% | 13.51% |
| Liquidia Corporation (LQDA)vs › | $2.34B | -32.45% | -449.54% | -390.50% | -1635.66% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 42.26% | 35.06% | 13.24% | -28.82% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.38B | -42.22% | -21.11% | -21.11% | -21.11% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.38B | -867.87% | -840.98% | -774.76% | -1234.34% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | -0.74% | -3.89% | -12.55% | -17.88% |
| Pharvaris N.V. (PHVS)vs › | $2.17B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
18.0%
Operating Margin
-3.6%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -29.33% |
| 2026-03-31 | 3.76% |
| 2025-12-31 | -13.51% |
| 2025-09-30 | 277.30% |
| 2025-06-30 | -139.84% |
| 2025-03-31 | -104.93% |
| 2024-12-31 | -67.60% |
| 2024-09-30 | -259.38% |
| 2024-06-30 | -12.96% |
| 2024-03-31 | -29.39% |
| 2023-12-31 | -9.64% |
| 2023-09-30 | -23.06% |
| 2023-06-30 | -16.85% |
| 2023-03-31 | 3.21% |
| 2022-12-31 | 53.37% |
| 2022-09-30 | 61.12% |
| 2022-06-30 | 74.44% |
| 2022-03-31 | 68.51% |
| 2021-12-31 | 66.14% |
| 2021-09-30 | 75.87% |
| 2021-06-30 | 70.50% |
| 2021-03-31 | 61.53% |
| 2020-12-31 | 31.77% |
| 2020-09-30 | 52.04% |
| 2020-06-30 | 17.31% |
| 2020-03-31 | 68.29% |
| 2019-12-31 | 3.58% |
